ENRICH trial results comparing minimally invasive trans-sulcal parafascicular surgery (MIPS) to standard care are encouraging but need replication in a larger trial, one outside expert says.
The results highlight the need for close monitoring and optimized multidisciplinary care for long-term adverse events after COVID-19 in patients with rheumatic disease.